<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741442</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA806-501</org_study_id>
    <nct_id>NCT00741442</nct_id>
  </id_info>
  <brief_title>A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout</brief_title>
  <official_title>Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether RDEA806 is effective in the treatment of
      hyperuricemia in gout patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the proportion of subjects whose serum uric acid (sUA) level is &lt;6.0 mg/dL following 4 weeks of continuous treatment with RDEA806.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of subjects whose sUA levels are &lt;6.0 mg/dL, &lt;5.0 mg/dL and &lt;4.0 mg/dL, at each visit.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the absolute and percent reduction from baseline in sUA levels</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate percent change in 24-hour urine uric acid level</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA806 400 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA806 400 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA806</intervention_name>
    <description>Uricosuric agent for the treatment of gout</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is hyperuricemic: screening serum uric acid â‰¥8 mg/dL.

          -  Patient meets one or more of the 1977 ARA criteria for the diagnosis of gout.

          -  Patient is willing and able to give informed consent and adhere to visit/protocol
             schedules

          -  All female subjects of child-bearing potential must agree to use a barrier method of
             birth control (e.g. condom, diaphragm or cap).

        Exclusion Criteria:

          -  Consumes more than 14 drinks of alcohol per week.

          -  History or suspicion of drug abuse.

          -  History of kidney stones, rheumatoid arthritis or other autoimmune disease,
             significant cardiac dysfunction.

          -  Diabetes Mellitus requiring treatment

          -  Confirmed or suspected HIV-1 infection.

          -  Malignancy, except treated non-melanomatous skin cancer and cervical dysplasia.

          -  Uncontrolled hypertension.

          -  Inadequate renal function.

          -  Hemoglobin &lt; 8 g/dL (males) or &lt; 7 g/dL (females).

          -  ALT, AST , or GGT 2 x ULN

          -  Active peptic ulcer disease.

          -  Requires long-term use of salicylates; thiazide diuretics; losartan; azathioprine;
             mercaptopurine; theophylline; IV colchicine; cyclosporine; cyclophosphamide;
             pyrazinamide; sulfamethoxazole; trimethoprim.

          -  Pregnant or breast feeding.

          -  Use of an investigational drug within 4 weeks prior to study drug administration.

          -  Known hypersensitivity or allergy to RDEA806 or colchicine or any components in their
             formulations.

          -  Any other medical or psychological condition which, in the opinion of the
             investigator, might create undue risk to the subject or interfere with the subject's
             ability to comply with the protocol requirements, or to complete the study.

          -  History of cardiac abnormalities including abnormal and clinically relevant ECG
             changes.

          -  Conditions predisposing to QT prolongation.

          -  Any use of concomitant medications that prolong the QT/QTc interval within 14 days
             prior to Day 1.

          -  Subjects with a QTcF interval &gt;450 milliseconds at screening or on Day -1 or at
             pre-dose (Hour 0) on Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Hingorani, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <disposition_first_submitted>January 7, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 7, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 6, 2014</disposition_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

